Chronic Urticaria Or Hives - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 65
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C8A9569E78AEN
Leaflet:

Download PDF Leaflet

Chronic Urticaria Or Hives - Pipeline Review, H2 2016
Chronic Urticaria Or Hives - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2016, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 2 and 3 respectively for Chronic Urticaria Or Hives.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Chronic Urticaria Or Hives Overview
Therapeutics Development
Pipeline Products for Chronic Urticaria Or Hives - Overview
Chronic Urticaria Or Hives - Therapeutics under Development by Companies
Chronic Urticaria Or Hives - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Chronic Urticaria Or Hives - Products under Development by Companies
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
Biofrontera AG
ELORAC, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
GlaxoSmithKline Plc
Mabtech Limited
Mycenax Biotech Inc.
Novartis AG
Panacea Biotec Limited
Synermore Biologics Co Ltd
Chronic Urticaria Or Hives - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BF-Derm-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cidoxepin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2646264 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDP-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ligelizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
quilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chronic Urticaria Or Hives - Dormant Projects
Chronic Urticaria Or Hives - Discontinued Products
Chronic Urticaria Or Hives - Product Development Milestones
Featured News & Press Releases
Jun 12, 2015: Novartis reports new analysis showing Xolair improving quality of life by 78% for chronic spontaneous urticaria patients
Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines
May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives
Mar 21, 2014: Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria
Mar 06, 2014: Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines
Jan 24, 2014: Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch
Oct 11, 2013: FDA Files Genentech’s Supplemental Biologics License Application of Xolair for Chronic Idiopathic Urticaria
Sep 30, 2013: Novartis to reveal landmark Phase III results of omalizumab at upcoming EADV 2013 congress
Jun 26, 2013: Novartis Reports New Phase III Data Showing Omalizumab Significantly Improves Itch In Patients With Severe Form Of CSU
Mar 20, 2013: Omalizumab Shows Promise In Eliminating Symptoms Of Chronic Urticaria, Study Finds
Feb 24, 2013: Genentech Reports Omalizumab Meets Primary Endpoint In Phase III Results In Patients With Chronic Form Of Hives Who Failed Standard Therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 65

LIST OF TABLES

Number of Products under Development for Chronic Urticaria Or Hives, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H2 2016
Chronic Urticaria Or Hives - Pipeline by ELORAC, Inc., H2 2016
Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Chronic Urticaria Or Hives - Pipeline by Genentech, Inc., H2 2016
Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2016
Chronic Urticaria Or Hives - Pipeline by Mabtech Limited, H2 2016
Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc., H2 2016
Chronic Urticaria Or Hives - Pipeline by Novartis AG, H2 2016
Chronic Urticaria Or Hives - Pipeline by Panacea Biotec Limited, H2 2016
Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Chronic Urticaria Or Hives - Dormant Projects, H2 2016
Chronic Urticaria Or Hives - Discontinued Products, H2 2016 51

LIST OF FIGURES

Number of Products under Development for Chronic Urticaria Or Hives, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Chronic Urticaria Or Hives - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: